A current label-based comparison of Zenrelia and Apoquel for dogs with allergic itch, including vaccine warnings, infection risks, monitoring, and decision points.

Zenrelia and Apoquel are prescription immunomodulating drugs for dogs. Do not start, stop, switch, or combine them without a veterinarian's instructions.

Quick answer

Zenrelia and Apoquel are both oral JAK inhibitors labeled for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The biggest current label difference is Zenrelia's boxed warning about inadequate immune response to vaccines. Apoquel does not carry that boxed vaccine warning, but it still has immune-system, infection, demodicosis, neoplasia, pregnancy/lactation, and drug-combination cautions.

If a dog is due for vaccines, has uncertain vaccine status, or has a legally required rabies timing issue, Zenrelia requires careful planning with the veterinarian. If a dog has serious infection, recurrent demodicosis, neoplasia history, or needs other systemic immunosuppressants, both labels deserve close attention.

Side-by-side comparison

Feature	Zenrelia	Apoquel
Active ingredient	Ilunocitinib	Oclacitinib
Drug class	JAK inhibitor	JAK inhibitor
U.S. indication	Control of allergic itch and atopic dermatitis in dogs at least 12 months old	Control of allergic itch and atopic dermatitis in dogs at least 12 months old
Route	Oral	Oral
Food	Label says with or without food	Label says with or without food
Vaccine warning	Boxed warning: risk of inadequate immune response to vaccines; do not vaccinate while receiving Zenrelia and follow label stop/withhold timing.	No boxed vaccine warning in the current Apoquel label reviewed for this article.
Serious infection	Not for use in dogs with serious infections	Not for use in dogs with serious infections
Neoplasia language	New benign and malignant neoplastic conditions observed in clinical studies; weigh risks in dogs with neoplasia history.	New benign and malignant neoplastic conditions observed in studies and reported post-approval; may exacerbate neoplastic conditions.
Breeding, pregnancy, lactation	Safe use not evaluated	Not for use in breeding, pregnant, or lactating dogs
Other systemic immunosuppressants	Safe use with glucocorticoids, cyclosporine, or other systemic immunosuppressants not evaluated	Same practical caution: not evaluated with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents

The vaccine issue is the key Zenrelia differentiator

Zenrelia's current U.S. label includes a boxed warning for inadequate immune response to vaccines. The label states that dogs receiving Zenrelia are at risk of an inadequate immune response, that vaccines should not be administered to a dog receiving Zenrelia, and that Zenrelia should be discontinued before vaccination and withheld after vaccination according to the label.

FDA's safety-related labeling-change page notes that Zenrelia's boxed warning was revised in September 2025 to remove earlier language about fatal vaccine-induced disease from modified live virus vaccines, while retaining the inadequate immune response concern. That means older online summaries may be out of date in both directions: some may overstate the old wording, while others may understate the current vaccine planning requirement.

Practical questions before Zenrelia:

Is the dog current on rabies, core, and lifestyle vaccines?
Are any vaccines due during the expected treatment period?
Is boarding, grooming, daycare, travel, or local law tied to vaccination timing?
If vaccination is needed, how long should Zenrelia be stopped before and after?
What itch-control bridge is safest during a Zenrelia vaccine hold?

Infection and immune monitoring

Both drugs modulate immune signaling. That does not mean every treated dog will get infections, but it does mean skin and ear rechecks matter.

Zenrelia's label says dogs should be monitored for infections and lists concerns including adenoviral hepatitis and pancreatitis, demodicosis, interdigital furunculosis, coccidiosis, pneumonia, and exacerbation of subclinical or uncomplicated infections. It also warns about progressive or persistent decreases in red blood cell measures without an appropriate reticulocyte response.

Apoquel's label says dogs receiving Apoquel should be monitored for infections, including demodicosis, and neoplasia. It says the drug may increase susceptibility to infection and may exacerbate neoplastic conditions.

For either drug, ask whether baseline and follow-up bloodwork are appropriate, especially if therapy is expected to be long term.

Which is safer?

There is no responsible universal answer. "Safer" depends on the dog:

Patient situation	More important question
Vaccines due soon	Can Zenrelia be used without interfering with required vaccination timing?
Serious skin infection	Should either JAK inhibitor wait until infection is controlled?
Recurrent demodicosis	Does the risk-benefit balance favor a non-JAK option such as Cytopoint or another plan?
History of cancer or new masses	Should masses be evaluated before immunomodulating therapy?
Concurrent steroids or cyclosporine	Is combination therapy necessary, and what monitoring plan justifies it?
Puppy under 12 months	Neither drug is labeled for this age.

Effectiveness expectations

Both drugs are intended to reduce allergic itch and help control atopic dermatitis, not to diagnose the underlying cause. If a dog does not improve, that may mean the wrong drug was chosen, but it may also mean fleas, mites, yeast, bacteria, otitis, food allergy, poor adherence, or an environmental trigger is still active.

If the drug works but itch returns whenever it is stopped, that supports chronic allergic disease but does not identify the trigger. A long-term plan may still need flea prevention, diet trial, allergy testing, immunotherapy, bathing, ear maintenance, and flare instructions.

Switching between Zenrelia and Apoquel

Do not switch directly using leftover tablets. The veterinarian needs to account for:

Current infection status
Vaccine timing
Last dose and expected washout
Whether steroids, cyclosporine, Cytopoint, or other drugs are being used
Any abnormal lab results
Whether itch is severe enough to need a bridge plan

The risk of casual switching is that the dog receives overlapping immunomodulation or that a new adverse sign is incorrectly attributed.

When to ask about Cytopoint or referral

Ask about Cytopoint, allergen-specific immunotherapy, or referral to a veterinary dermatologist if:

Vaccination timing makes Zenrelia difficult.
The dog cannot tolerate or respond to oral JAK inhibitors.
There are repeated skin or ear infections.
Allergy medication helps only briefly.
The dog has a cancer history, recurrent demodicosis, or complex comorbidities.
The owner wants a long-term plan beyond repeated flare suppression.

Bottom line

Zenrelia and Apoquel look similar at the indication level, but their labels are not identical. Zenrelia's vaccine warning is the major decision point. Apoquel has longer market familiarity but still requires immune, infection, and neoplasia awareness. For either drug, the strongest plan is not "pick a pill." It is confirm the dog is a good candidate, control infections and parasites, plan vaccines, monitor over time, and revisit the diagnosis if the response is incomplete.